Resources

Dr. Jan Griffin, amyloidosis cardiologist at the Medical University of South Carolina, discussed how ATTR affects the heart and explored advances in treatments for ATTR-CM.

This white paper summarizes advancements in the field, key challenges, and consensus priorities for the amyloidosis research community that were identified and discussed by attendees of the 2024 ARC Research Roundtable Meeting. The information presented in this paper represents the opinions and outlooks of the global amyloidosis experts.

Sabrina Rebello, ARC's Senior Research Manager, presented an in-depth overview of key insights from our Annual Community Survey. This webinar focused on understanding the experiences of patients and caregivers throughout their diagnostic journey and ongoing care.

Lovley, A., Hsu, K., LaGasse, K. et al. Reliability and validity of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire impact scales. J Patient Rep Outcomes 9, 44 (2025). https://doi.org/10.1186/s41687-025-00880-7

Kristen Hsu, ARC’s Executive Director of Research, presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.

Dr. Meghan Beier, psychologist at the Rowan Center for Behavioral Medicine, explored the emotional aspects of amyloidosis. She discussed mental health issues in amyloidosis and present strategies for coping.

Dorbala, S, Adigun, R, Alexander, K. et al. Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. J Am Coll Cardiol Img. null2025, 0 (0) . https://doi.org/10.1016/j.jcmg.2024.11.003

Dr. Sarah Cuddy, cardiologist at Brigham and Women's Hospital, explored the basics of amyloidosis. She presented an introduction to amyloidosis, the different types, and the available treatments. The webinar concluded with a Q&A session.